Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

BACKGROUND: Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of plasma amyloid-beta (Aβ)42/Aβ40 ratio measured by an antibody-free mass-spectro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual-Lucas, María, Allué, José Antonio, Sarasa, Leticia, Fandos, Noelia, Castillo, Sergio, Terencio, Jose, Sarasa, Manuel, Tartari, Juan Pablo, Sanabria, Ángela, Tárraga, Lluís, Ruíz, Agustín, Marquié, Marta, Seo, Sang Won, Jang, Hyemin, Boada, Mercè
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814201/
https://www.ncbi.nlm.nih.gov/pubmed/36604729
http://dx.doi.org/10.1186/s13195-022-01143-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814201/
https://www.ncbi.nlm.nih.gov/pubmed/36604729
http://dx.doi.org/10.1186/s13195-022-01143-z

Ejemplares similares